Menu
ETF
Annual · values20262025202420232022202120202019201820172016
Operating Cash Flow-5.13 M USD-4.63 M USD-3.53 M USD-2.99 M USD-2.81 M USD-297055 USD-894470 USD-1.11 M USD-92858 USD-147923 USD
Depreciation & Amortization193797 USD285054 USD287722 USD330143 USD308741 USD160108 USD72188 USD37011 USD0 USD
Stock-Based Compensation2.63 M USD1.41 M USD499856 USD732130 USD365000 USD2.00 M USD252700 USD1.76 M USD7770 USD
Capital Expenditures5324 USD92043 USD51761 USD79304 USD81595 USD4163 USD
Cash Flow from Investing-5324 USD-92043 USD-51761 USD-79304 USD-81595 USD66994 USD-404163 USD
Cash Flow from Financing5.40 M USD8.54 M USD2.09 M USD160074 USD7.63 M USD371873 USD430250 USD1.98 M USD65762 USD174900 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-5.14 M USD-4.72 M USD-3.58 M USD-3.07 M USD-2.89 M USD-1.11 M USD

Nutriband Inc. is a pharmaceutical and healthcare company specializing in the development and commercialization of transdermal products and technologies. The primary focus of Nutriband is to improve the safety and efficacy of drug delivery systems. By leveraging transdermal adhesive materials, Nutriband Inc. offers an innovative approach to drug administration that bypasses the gastrointestinal tract and liver, enabling a more direct and controlled delivery to the bloodstream. This approach can reduce side effects and improve patient compliance. Nutriband's technologies have broader applications not only in delivering medications effectively but also in enhancing safety in medical treatments, which is critical across pharmaceutical and biotechnology industries. With its commitment to therapeutic advancements, Nutriband Inc. plays an essential role in the ongoing transformation of drug delivery systems, potentially impacting a variety of treatment areas and improving patients' experiences across different healthcare settings.